The 20 Largest Medical Device Companies In the World

Share

Alcon Novartis logoNo. 17: Novartis

Fort Worth, Texas

www.alcon.com

2016 RANK: 11

Revenue: $5,812,000,000*

Fiscal year ending: Dec. 31, 2016

Employees: 19,000

R&D Spend: $486,000,000

 

Key Personnel:

Mike Ball, CEO; Kim Adler, head, global communications; Laurent Attias, head, strategy, BD&L & market access; Royce Bedward, SVP & general counsel; Ian Bell, president, EMEA; Sergio Duplan, president, North America; David Endicott, COO; Camila Finzi, president, Latin America & the Caribbean; Franck Leveiller, head, global R&D; Merrick McCracken, SVP, HR; Ed McGough, SVP, global manufacturing & technical operations; Jim Murphy, president, Japan; David Murray, CFO; Rajkumar Narayanan, president, Asia; Michael Onuscheck, head, Alcon Surgical; Dave Schoening, SVP quality; Eric van Oppens, head, global strategic initiatives

Description:

Alcon’s surgical and vision care businesses together boast one of the world’s widest selections of eye care devices. Products range from sophisticated eye surgery equipment to advanced contact lenses. Alcon went through a transition year in 2016, according to the annual report of Alcon’s parent company Novartis. There was more of a concentration on eye care devices – as well as R&D investment and new systems and capabilities to boost relationships with customers. Rumors once again swirled last year about a possible private equity spinout or IPO for Alcon; with CEO Joe Jimenez turning the corner office over to Dr. Vasant Narasimhan early next year, those rumors are not likely to go away.

* Revenues from Novartis’ Alcon segment.

Download the full Big 100 list here.

And you can also pick up a free hard copy of the Big 100 issue at DeviceTalks Boston on Oct. 2!

Next>>

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8 9 10 11

Comments

  1. Chris Newmarker says:

    Apologies. We had to fix a technical glitch with the Big 100 spreadsheet download. If you fill out the sign-up form now, you should get an email with a link to download the spreadsheet, instead of last year’s Big 100 edition.

  2. Chris, Thank you for the update. I just downloaded the Big 100.

Speak Your Mind

*